Which Party Is Responsible for Reporting the Investigator's Financial Interests With the Sponsor Directly to the FDA: The Sponsor's 21 CFR Part 54 Burden

The sponsor is the party responsible for reporting an investigator's financial interests with the sponsor directly to the FDA. Under 21 CFR Part 54, the sponsor collects the information from each investigator, certifies to the agency that it has done so, and files the disclosures in marketing applications such as an NDA, BLA, or 510(k). The investigator's legal duty is to disclose to the sponsor, not to the FDA, and site staff, IRBs, and CROs carry no direct reporting obligation to the agency.

That split is the whole answer in one breath, but the details matter because misreading them is a common compliance failure. A clinical investigator who assumes the site files with the FDA may leave the sponsor without a signed financial disclosure, which can stall an application. A sponsor that treats the disclosure as a formality may discover that a single missing certification triggers a formal agency request. The sections below walk through the regulatory basis, who holds each piece of the obligation, the timing, the form-level mechanics, and the edge cases that decide whether a filing survives review.

The Regulatory Basis: 21 CFR Part 54 and the Financial Disclosure Rule

21 CFR Part 54 is the FDA's financial disclosure regulation for clinical investigators, and it took effect on February 2, 1999, following the final rule published in the Federal Register on February 2, 1998. The rule applies to applicants who submit human drug, biologic, and device marketing applications, and it defines who must disclose, what must be disclosed, and how the agency receives it. The companion regulation for institutional review boards and clinical investigators sits at 21 CFR Part 50, which addresses informed consent and investigator obligations. Part 54 is where the reporting chain to the FDA lives.

The regulation separates two audiences. Investigators disclose to the sponsor. Sponsors report to the FDA. That two-step structure is deliberate: the agency wants a single accountable party for each application, and the sponsor is the applicant of record. The FDA's guidance document "Financial Disclosure by Clinical Investigators," issued in February 2013, restates the chain and explains how the agency reviews the certifications and disclosure forms submitted in an application.

Part 54 covers any clinical investigator who participates in a covered clinical study, meaning a study submitted in support of a marketing application. The rule's scope extends to investigators who were added mid-study and to those who dropped out, because the sponsor must account for every investigator's financial interests during the study and for one year after its completion. The agency treats the applicant, not the site, as the point of accountability, and that framing drives every downstream practice described in this article.

Who Reports What: Investigator, Sponsor, Site Staff, IRB, and CRO Roles

The investigator's reporting obligation runs to the sponsor, and the mechanism is a signed financial disclosure form or a certification that no disclosable interests exist. The investigator must disclose significant payments, equity interests, proprietary interests, and arrangements such as consulting fees or honoraria that could affect the study's conduct. The FDA's 2013 guidance lists the reportable categories and explains that the investigator signs the form and returns it to the sponsor, who keeps it in the study file for the application. The investigator never transmits that form to the FDA directly.

The sponsor holds the direct reporting obligation. Under Part 54, the applicant must certify to the FDA that it has collected the required information from each investigator, or it must submit the actual disclosure forms with the application. The sponsor also must report any changes in an investigator's financial interests that arise during the study and within one year after its completion. The FDA receives the certification or the forms as part of the marketing application, which is why the agency's review divisions see them alongside the clinical data.

Site staff, IRBs, and CROs occupy a different lane. An IRB reviews financial disclosures under its conflict-of-interest policies and may require management plans, but it does not file with the FDA. A CRO acting on the sponsor's behalf may collect the forms and maintain the files, yet the sponsor remains the applicant and signs the certification. Coordinators and sub-investigators disclose through the investigator of record, and the FDA's guidance treats the investigator's signature as the operative disclosure. When a CRO is delegated the collection task, the delegation should be documented in the clinical trial agreement and the sponsor's oversight records, because the agency looks to the applicant if a form is missing.

The Sponsor's Four-Step Reporting Sequence

The sponsor's reporting work follows a fixed sequence, and each step has a visible deliverable. The sequence starts before enrollment and ends with the marketing application, with a look-back period that extends past study close. The steps below reflect the order in which the FDA's guidance expects the work to occur.

1: Collect a signed financial disclosure form or certification from every investigator before the study begins. The form must cover the reportable categories in Part 54, and the sponsor should retain the original signed document in the trial master file. A missing form at this stage is the most common finding in application reviews. 2: Track changes during the study and for one year after completion. If an investigator acquires a new equity interest or a consulting arrangement, the sponsor must update the disclosure and reflect the change in the application. The one-year window is a fixed rule, not a grace period the sponsor can shorten. 3: Prepare the certification or the disclosure forms for the application. The sponsor either certifies that it has collected the information or submits the completed forms. The certification is a signed statement, and the forms carry the investigator's signature and the sponsor's identification of the study. 4: Submit with the marketing application and respond to agency requests. The FDA may ask the sponsor to clarify or supplement a disclosure, and the sponsor must respond within the application's review timeline. The agency's 2013 guidance describes the review divisions' practice of requesting additional information when a disclosure is incomplete.

If a step fails — a form is unsigned, an investigator's interest was never captured, or a change went unreported — the sponsor has a narrow repair window. The fix is a documented supplemental disclosure filed with the application, plus a written explanation of the gap. The FDA's guidance allows the applicant to submit additional information during review, but it does not waive the underlying obligation. A sponsor that discovers a missing form after approval may face a post-marketing request, and the file should be corrected before any subsequent application relies on the same study.

Timing and Deadlines: Enrollment, Study Close, and the One-Year Look-Back

Timing is where the reporting obligation gets tested. The investigator's disclosure is due before the investigator begins the study, and the sponsor should not enroll a subject under an investigator whose form is outstanding. The FDA's guidance frames the pre-study collection as the baseline, and the sponsor's certification depends on having that baseline for every investigator. A form signed after enrollment is better than no form, but it invites questions about what the investigator's interests were at the start.

The one-year look-back is the rule most often misread. The sponsor must report changes in an investigator's financial interests that occur during the study and for one year after the study's completion. The clock runs from the completion date, not from the last subject visit or the database lock, and the sponsor should document the completion date it uses. The FDA's guidance explains that the look-back exists because an investigator's interests can shift after the study ends, and the agency wants the application to reflect the full window.

The application submission itself has no separate Part 54 deadline beyond the application's own filing requirements. The disclosure materials travel with the application, so the practical deadline is the submission date. If the sponsor is assembling a 510(k) or an NDA, the financial disclosure section should be complete before the application is filed, and the sponsor should build the collection step into the study start-up checklist. A sponsor that waits until submission to collect forms from a dozen sites will find the review timeline tight.

Form Mechanics: The 3454 and 3455 Certification and Disclosure Paths

The FDA's financial disclosure forms carry the agency's form numbers, and the sponsor's choice between them determines what the agency sees. Form FDA 3454 is the certification that the sponsor has collected the required information and that no disclosable interests exist, or that the interests have been disclosed. Form FDA 3455 is the disclosure form that lists an investigator's reportable interests and the steps taken to manage them. The sponsor files one or the other, or a combination, depending on what the investigators reported.

The certification path is faster but narrower. If every investigator certifies no disclosable interests, the sponsor can submit Form FDA 3454 and avoid attaching individual disclosure forms. If any investigator discloses an interest, the sponsor must submit Form FDA 3455 for that investigator, and the form must describe the interest and any steps the sponsor took to minimize bias. The FDA's 2013 guidance explains that the agency reviews the 3455 to assess whether the interest could have affected the study's conduct.

The forms carry signature requirements that trip up sponsors. The investigator signs the disclosure, and the sponsor's authorized official signs the certification. A form signed by a coordinator or a CRO project manager without documented delegation is a defect the agency may flag. The sponsor should keep the signed originals and a log that maps each investigator to the form submitted, because the FDA may ask for the log during an inspection. The forms are filed with the application, not sent separately, and the sponsor's regulatory operations team should treat them as part of the application's administrative section.

Site-Level Practice: What the Investigator Actually Signs and Returns

At the site level, the investigator's practical obligation is to sign and return the sponsor's financial disclosure form, and the site should keep a copy in its regulatory binder. The form arrives during site start-up, often alongside the confidentiality agreement and the clinical trial agreement, and the investigator should complete it before the first subject is enrolled. The site's regulatory coordinator typically tracks the form's return, but the investigator's signature is the operative act. A site that returns the form late, or returns it unsigned, creates a gap the sponsor must close.

The disclosure categories the investigator must consider include significant payments, equity interests, proprietary interests, and arrangements such as consulting fees, honoraria, and grants. The FDA's guidance defines significant payments with a monetary threshold, and the investigator should apply the threshold to the payments received during the study and the one-year look-back. The site's finance office can supply the payment records, and the investigator should reconcile them against the form before signing.

The site should not send the form to the FDA. That is the most common misconception, and it produces wasted effort and misplaced confidence. The FDA's guidance is clear that the investigator discloses to the sponsor, and the sponsor files with the agency. A site that mails a form to an FDA office has not satisfied the sponsor's obligation, and the sponsor may still be missing the form. The site's copy belongs in the regulatory binder, and the sponsor's copy belongs in the trial master file.

Common Compliance Failures and How Sponsors Repair Them

The failures that matter most are the ones the FDA sees in application reviews. A missing form for one investigator, an unsigned form, a form that omits a consulting arrangement, and a change in interests that was never updated are the recurring findings. The FDA's 2013 guidance and the agency's inspection observations describe these gaps, and each has a repair path. The sponsor's repair is a supplemental submission with a written explanation, not a silent correction.

A failure case worth naming: a sponsor collects forms at study start but never revisits them during the one-year look-back. An investigator who joins a sponsor's advisory board after the study closes has a new reportable interest, and the sponsor's file is now incomplete. The FDA may request the updated disclosure during review, and the sponsor must produce it. The fix is a calendar reminder tied to the study completion date, with a named owner in the regulatory affairs group.

Another failure case involves the CRO delegation. A sponsor delegates collection to a CRO, the CRO's project manager signs the forms on the investigator's behalf, and the sponsor submits the forms without checking the signatures. The FDA's review may flag the signature defect, and the sponsor must obtain the investigator's actual signature. The repair is a re-collection with a corrected form, plus a note in the file explaining the delegation and the correction. The lesson is that delegation transfers the task, not the accountability.

Device Studies, Foreign Sites, and the 510(k) Path

Device studies follow the same Part 54 structure, but the application type changes the filing mechanics. A 510(k) submission includes the financial disclosure certification or forms, and the sponsor's choice between the 3454 and 3455 paths depends on what the investigators reported. The FDA's guidance applies to device applications, and the agency's review divisions expect the disclosure section to be complete before the submission is filed. A device sponsor that treats the disclosure as a drug-only requirement will find the gap at the review stage.

Foreign sites add a layer. The sponsor must collect disclosures from investigators at foreign sites that submit data in support of a U.S. application, and the FDA's guidance addresses the foreign-site scenario. The form's categories apply, and the sponsor should translate the form when needed and document the translation. The one-year look-back still runs, and the sponsor's file should reflect the foreign site's completion date. A foreign investigator who signs a locally worded form that omits a Part 54 category creates a gap the sponsor must close with a supplemental disclosure.

The 510(k) path also raises the question of which studies are covered. A study submitted in support of a 510(k) is a covered clinical study, and the investigators in that study are covered. The sponsor should map each study in the application to its investigators and confirm the forms are on file. The FDA's guidance explains that the agency may request the disclosure materials during review, and the sponsor's response should be ready before the request arrives.

Why the Investigator and the FDA Are Not the Reporting Parties

The investigator's duty is disclosure to the sponsor, and the FDA's guidance is explicit that the investigator does not file with the agency. The investigator's signature on the form is the disclosure act, and the sponsor's submission is the reporting act. That division is the answer to the keyword question, and it is also the source of the most common misunderstanding. An investigator who believes the site files with the FDA may not return the sponsor's form promptly, and the sponsor's certification then rests on an incomplete file.

The FDA's role is receiver and reviewer, not collector. The agency reviews the certification or forms in the application, and it may request additional information when a disclosure is incomplete. The FDA does not contact investigators directly to collect forms, and it does not maintain a separate investigator filing system for Part 54 disclosures. The agency's inspection program may review the sponsor's file, and the investigator's site may be inspected for the underlying records, but the reporting chain stays with the sponsor.

This division carries a practical consequence for contracts. The clinical trial agreement should state that the investigator will complete the sponsor's financial disclosure form and return it before enrollment, and the agreement should identify the sponsor's contact for the form. The site's regulatory binder should hold the signed copy, and the sponsor's trial master file should hold the original. A contract that is silent on the form leaves the timing to chance, and the sponsor's certification depends on the timing.

Audit Readiness: What Inspectors Ask For and Where the File Lives

An FDA inspection of a sponsor or a site will ask for the financial disclosure file, and the file's completeness is the test. The inspector may ask for the signed forms, the certification, the log that maps investigators to forms, and the documentation of any changes during the one-year look-back. The sponsor's trial master file should hold the originals, and the site's regulatory binder should hold the copies. A file that is missing one investigator's form is a finding, and the sponsor's response should describe the repair.

The inspector may also ask how the sponsor tracked changes. A sponsor that has no calendar reminder or named owner for the look-back will struggle to show that it met the obligation. The file should include the study completion date, the look-back window, and the evidence of any updated disclosures. The FDA's guidance describes the agency's review practice, and the inspection practice follows the same logic. The sponsor's quality system should treat the financial disclosure file as a controlled record.

The site's inspection readiness is simpler. The regulatory binder should hold the signed form, the correspondence with the sponsor about the form, and any updated disclosure. The investigator should be able to explain the categories and the timing if asked. A site that cannot produce the form has a gap, and the sponsor's file may be the only complete record. The site should reconcile its binder against the sponsor's log before an inspection, and the reconciliation should be documented.

FAQ

Does the investigator ever report financial interests to the FDA directly?

No. The investigator discloses to the sponsor, and the sponsor reports to the FDA through the marketing application. The FDA's 2013 guidance on financial disclosure describes the investigator's signature as the disclosure act and the sponsor's submission as the reporting act. An investigator who sends a form to an FDA office has not satisfied the sponsor's obligation, and the sponsor may still be missing the form. The site should keep its copy in the regulatory binder and return the original to the sponsor.

What happens if the sponsor cannot obtain a disclosure from one investigator?

The sponsor must still account for that investigator in the application, and the gap should be documented with a written explanation. The FDA may request additional information during review, and the sponsor's response should describe the collection efforts and any supplemental disclosure obtained. A missing form for one investigator can delay the application's review, so the sponsor should resolve the gap before submission. The repair is a supplemental filing, not a silent omission.

Is the one-year look-back measured from the last subject visit or the study completion date?

It runs from the study's completion date, and the sponsor should document the date it uses. The FDA's guidance ties the look-back to the study's completion, and the sponsor's file should show the completion date and the window. A sponsor that measures from the last subject visit may close the window early and miss a reportable change. The calendar reminder should be tied to the documented completion date.

How do Form FDA 3454 and Form FDA 3455 differ in practice?

Form FDA 3454 is the certification that the sponsor has collected the required information, and Form FDA 3455 is the disclosure form that lists an investigator's reportable interests. The sponsor files the 3454 when no disclosable interests exist, and the 3455 when an investigator discloses an interest. The 3455 must describe the interest and any steps the sponsor took to minimize bias. The choice between the forms depends on what the investigators reported, not on the sponsor's preference.

Can a CRO sign the financial disclosure forms on the investigator's behalf?

No. The investigator's signature is the operative disclosure, and a CRO project manager's signature without documented delegation is a defect. The CRO may collect the forms and maintain the files under a documented delegation, but the investigator must sign. A sponsor that submits a CRO-signed form may face an agency request for the investigator's actual signature. The repair is a re-collection with a corrected form and a note in the file.

Do foreign investigators at sites outside the United States have to complete the same form?

Yes, when their data support a U.S. marketing application. The sponsor must collect the disclosures from foreign investigators, and the form's categories apply. The sponsor should translate the form when needed and document the translation. The one-year look-back still runs, and the sponsor's file should reflect the foreign site's completion date. A locally worded form that omits a Part 54 category creates a gap the sponsor must close.

What should a site do if the sponsor's form arrives after enrollment has started?

The investigator should complete and return the form promptly, and the site should document the timing in the regulatory binder. The sponsor should treat the late form as a gap and consider a supplemental disclosure if the investigator's interests changed during the interval. The site should not wait for the sponsor to ask again, and the investigator should reconcile the form against the payment records before signing. The goal is a complete file, even if the timing was imperfect.

This article is general educational information about FDA financial disclosure requirements and is not legal, regulatory, or compliance advice. The obligations described apply to U.S. marketing applications and may differ for other jurisdictions or application types, so check the current FDA guidance and your institution's policies before acting. Consult a qualified regulatory professional or attorney for advice on a specific study or filing.